trial

A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)

NCTId NCT03565068
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 75 (actual)
Sponsored by Merck Sharp & Dohme LLC
Primary completion 2020-04-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
75 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2018-06-20
Primary completion
2020-04-03
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
MK-8189Background AAP Therapy

Sponsors

Merck Sharp & Dohme LLCLead Sponsor

Sites

1 total
Glendale, United States

Facts & assertions

4 sourced
Enrollment
75
Phase
PHASE1
Primary Completion Date
2020-04-03
Status
COMPLETED
relationships
The graph out of here
drug
MK-8189
drug
Background AAP Therapy
drug
lead_sponsor
Merck Sharp & Dohme LLC
company
indication
Schizophrenia
indication
Schizophrenia
indication